The Indian Journal of Pediatrics

, Volume 70, Issue 1, pp 63–72

Long-term management of asthma

Symposium on Advances in Pediatrics-I

Abstract

Long-term management of asthma includes identification and avoidance of precipitating factors of asthma, pharmacotherapy and home management plan. Common precipitating factors include viral upper respiratory infections, exposure to smoke, dust, cold food and cold air. Avoidance of common precipitating factors has been shown to help in better control of asthma. Pharmacotherapy is the main stay of treatment of asthma. Commonly used drugs for better control of asthma are long and short acting bronchodilators, mast cell stabilizers, inhaled steroids, theophylline and steroid sparing agents. After assessment of severity most appropriate medications are selected. For mild episodic asthma the medications are short acting beta agonists as and when required. For mild persistent asthma: as and when required bronchodilators along with a daily maintenance treatment in form of low dose inhaled steroids or cromolyn or oral theophylline or leukotriene antagonists are required. Moderate persistent asthma should be treated with inhaled steroids along with long acting beta agonists for symptom control. For severe persistent asthma the recommended treatment includes inhaled steroids, long acting beta agonists with or without theophylline. If symptoms are not well controlled, a minimal dose of oral prednisolone preferably on alternate days may be needed in few patients. Patients should be followed up every 8–12 weeks. On each follow up visit patients should be examined by a doctor, compliance to medications should be checked and actual inhalation technique is observed. Depending on the assessment, medications may be decreased or stepped up. For exercise induced bronchoconstriction: cromolyn, short or long acting beta agonists or leukotriene antagonists may be used. In children with seasonal asthma, maintenance treatment according to assessed severity should be started 2 weeks in advance and continued throughout the season. These patients should be reassessed after discontinuing the treatment. Parents should be given a written plan for management of acute exacerbation at home

Key words

Long-term management of asthma Inhaled steroids Leukotriene antagonists ketotifen 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Djukanovic R, Rochewr, Wilson JWet al. Mucosal inflammation in asthma.Am Rev Respir Dis 1990; 140:434–457.Google Scholar
  2. 2.
    Consensus guidelines on management of childhood asthma in India.Indian Pediatr 1999; 36:157-165.Google Scholar
  3. 3.
    Asthma: a follow-up statement from an international pediatric asthma consensus group.Arch Dis Child 1992; 67:240-448.Google Scholar
  4. 4.
    National Heart Lung and Blood Institute and World Health Organization. Global initiative for asthma. National Institute of Health, Bethesda. 1995 Publication No. 95–3659.Google Scholar
  5. 5.
    National Heart Lung and Blood Institute. Expert panel report 2. Guideline for the diagnosis and management of asthma. National Institute of Health, Bethesda HD, 1997 Publication No. 97–4051.Google Scholar
  6. 6.
    The British guideline on asthma management review and position statement.Thorax 1997; 52 : S1-S21.Google Scholar
  7. 7.
    Pohharel P, Kabra SK, Kapoor SK, Pandey RM. Risk factors associated with bronchial asthma in school going children of rural Haryana.Indian J Pediatr 2001; 68:103–106.CrossRefGoogle Scholar
  8. 8.
    Ratageri VH, Kabra SK, Dwivedi SN, Seth V. Factors associated with severe asthma.Indian Pediatr 2000; 37:1072–1082.PubMedGoogle Scholar
  9. 9.
    Murray AB, Ferguson AC. Dust free bedroom in the treatment of asthmatic children with house dust mite allergy.Pediatrics 1983; 71:418–422.PubMedGoogle Scholar
  10. 10.
    Gavett SH, Koren HS. The role of particulate matter in exacerbation of atopic asthma.Int Arch Allergy Immunol 2001, 124:109–112.PubMedCrossRefGoogle Scholar
  11. 11.
    Duff AL, Pomeranz ES, Gelber LEet al. Risk factors for acute wheezing in infants and children: Viruses, passive smoking and IgE antibodies to inhalant allergies.Pediatrics 1993, 92:535–540.PubMedGoogle Scholar
  12. 12.
    Andrae S, Axelson O, Bjorksten Bet al. Symptoms of bronchial hyper reactivity and asthma in relation to environmental actor.Arch Dis Child 1988; 63:473–478.PubMedCrossRefGoogle Scholar
  13. 13.
    Dust mite allergens and asthma: Report of a second international workshop.J Allergy Clin Immunol 1992; 89 :1046-1060.Google Scholar
  14. 14.
    Htut T, Higenbottam TW, Gill GW, Darwin R, Anderson PB, Syed N. Eradication of house dust mite from homes of atopic asthmatic subjects: a double-blind trial.J Allergy Clin Immunol 2001; 107:55–60.PubMedCrossRefGoogle Scholar
  15. 15.
    Strachan DP. Moulds, mites and childhood asthma.Clin Exp Allergy 1993; 23:812–820.CrossRefGoogle Scholar
  16. 16.
    Roul F, Leaute-Labreze C, Perromat Met al. Sensitization to cockroach allergens evaluated by skin testing in children with alopic dermatitis.Ann Dermatol Venererol 2001; 128:115–117.Google Scholar
  17. 17.
    O’B Hourihane J. The threshold concept in food safety and its applicability to food allergy.Allergy 2001; 56 (Suppl) 67:86–89.PubMedCrossRefGoogle Scholar
  18. 13.
    Baker JC, Ayres JG. Diet and asthma.Respir Med 2000; 94:925–934.PubMedCrossRefGoogle Scholar
  19. 19.
    Molfino NA, Wright SC, Katz Iet al. Effect of low concentrations of ozone on inhaled allergen responses in asthmatic subjects.Lancet 1991; 338:199–203.PubMedCrossRefGoogle Scholar
  20. 20.
    Meeker DP, Wiedemann HP. Drug induced bronchospasm.Am Chest Med 1990; 11:163–177.Google Scholar
  21. 21.
    Schnall R, Landan LI. The protective effect of repeated short sprints in exercise induced asthma.Thorax 1998; 35:828–832.Google Scholar
  22. 22.
    Lenney W, Pedersens, Boner AL, Ebbutt A, Jenkin MN. Efficacy and safety of salmeterol in childhood asthma.Eur J Pediatr 1995; 154:983–998.PubMedCrossRefGoogle Scholar
  23. 23.
    Verbern AA, Frost C, Roorda FJ, Van Der Laag H, Kerreb un KF. One-year treatment with salmeterol combined with bedomethasone in children with asthma.Am J Resp Crit Care Med 1997; 156:688–695.Google Scholar
  24. 24.
    Russel G, Williams DA, Weiler P, Price F. Salmeterol xinofoate in children on high dose inhalation steroids.Annals Allergy Asthma Immunol 1995, 75:423–428.Google Scholar
  25. 25.
    Blake K, Pearlman DS, Scott C, Wang Y, Stahi E, Prevention of exercise induced bronchospasm in pediatric asthma patients. Compression of Salmeterol powder with salbutamol.Annals Allergy Asthma Immunol 1999; 82:205–211.Google Scholar
  26. 26.
    Greening AP, Ind PW, Northfield Met al. Added salmeterol versus higher dose corticosteroids in asthma patients with symptoms on existing inhaled corticosteroids.Lancet 1994; 344: 219–224.PubMedCrossRefGoogle Scholar
  27. 27.
    Bartow RA, Brogdem RN. Formeterol, An update of its pharmacologic properties and therapeutic efficacy in the management of asthma.Drugs 1998; 55:303–322.PubMedCrossRefGoogle Scholar
  28. 28.
    Becker AB, Simons FER, McMillan JLet al. Formoterol, a new long acting selective adrenergic receptor agonist: double blind comparisons with salbutamol and placebo in children with asthma.J Allergy Clin Immonol 1989; 84:891–895.CrossRefGoogle Scholar
  29. 29.
    Rolfe FG, Hughe JN, Armour CLet al. Inhibition of interleukins gene expression by dexamethasone.Immunology 1992, 77:494–499.PubMedGoogle Scholar
  30. 30.
    Mitchell JA, Belvisi MG, Akaraseree Mon RAet al. Induction of cyclo oxygenase 2 by cytokines in human pulmonary epithelial cells regulation by dexamethasone.Br J Pharmacol 1994; 113:1008.PubMedGoogle Scholar
  31. 31.
    Scarfone RJ, Fuchs SM, Nager ALet al. Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.Pediatrics 1993; 92:513–518.PubMedGoogle Scholar
  32. 32.
    Dahl R, Johansson SA. Importance of duration of treatment with inhaled budesonide on the immediate and late bronchial reaction.Eur Respir J 1998; 63 (suppl 122): 167–175.Google Scholar
  33. 33.
    Clark DJ, Clark RA, Lipworth BJ. Adrenal suppression with inhaled Budesonide and Fluticasone propionate given by large volume spacer to asthmatic children.Thorax 1996; 51:941–943.PubMedGoogle Scholar
  34. 34.
    Ferguson AC, Spier S, Manjra A, Versteegh FGAet al. Efficacy and safety of high-dose inhaled steroids in children with asthma: a comparison of fluticasone propionate with budesonide.J Pediatr 1999; 134:422–427.PubMedCrossRefGoogle Scholar
  35. 35.
    Agertoft L, Pedersen S. Effect of long —term treatment with inhaled corticosteroids on growth and pulmonary function in asthmatic children.Respir Med 1994; 88:373–381.PubMedCrossRefGoogle Scholar
  36. 36.
    Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma.N Engl J Med 2000; 343:1064–1069.PubMedCrossRefGoogle Scholar
  37. 37.
    The childhood asthma management program research group. Long-term effect of Budesonide or Nedocromil in children with asthma.N Engl J Med 2000; 343:1054–1063.CrossRefGoogle Scholar
  38. 38.
    Allen DB, Mullen MC, Mullen B. A meta analysis of the effect of oral and inhaled corticosteroid on growth.J Allergy Clin Immunol 1994; 93:967–976.PubMedCrossRefGoogle Scholar
  39. 39.
    Szefler SJ. A review of Budesonide inhalation suspension in the treatment of pediatric asthma.Pharmacotherapy 2001; 21: 195–120.PubMedCrossRefGoogle Scholar
  40. 40.
    Furukawa CT, Shapiro GG, Bierman Cwetal. A double blind study comprising the effectiveness of cromolyn and sustained release theophylline in childhood asthma.Pediatrics 1984; 74: 453.PubMedGoogle Scholar
  41. 41.
    Croce J, Negreiros EB, Mazzei JA, Isturiz G. A double blind, placebo-controlled comparison of sodium cromoglyeate and ketotifen in the treatment of childhood asthma.Allergy 1995, 50:524–527.PubMedCrossRefGoogle Scholar
  42. 42.
    Yasuhiro Kato, Kae Muraki, Michiko Fujitaka, Nobuo Sakura, Kazuhiro Ueda. Disodium cromoglyeate use in children and adolescents with asthma: correlation between plasma concentrations and protective effects for various inhalation methods.Ann Allergy Asthma Immunol 1999; 83:553–558.PubMedGoogle Scholar
  43. 43.
    De Benedictis FM, Tuteri G, Bertotto Aet al. Comparison of the protective effects of cromolyn sodium and nedocromil sodium in the treatment of exercise induced asthma in children.J Allergy Clinical Immunol 1994; 94:684–87CrossRefGoogle Scholar
  44. 44.
    Cherniack RM, Wasserman SI, Ramsdell JWet.al. A double blind multicentre group comparative study of the efficacy of nedocromil sodium in management of asthma.Chest 1990; 101: 1299–1302.Google Scholar
  45. 45.
    Childhood Asthma Management Program Research Group. Long-term effects of budesonide or Nedocromil in children with asthma.New Eng J Med 2000, 343:1054–1063.CrossRefGoogle Scholar
  46. 46.
    Kabra SK, Pandey RM, Singh R, Seth V. Ketotifen for asthma in children aged 5 to 15 years: a randomized placebocontrolled trial.Ann Allergy Asthma Immunol 2000; 85:46–52.PubMedGoogle Scholar
  47. 47.
    Legg J, Warner J. Asthma —The changing face of drug therapy.Indian J Pediatr 2000; 67:147–153.PubMedGoogle Scholar
  48. 48.
    Romanet S, Stremler-Lebel N, Magnan A, Dubus JC. Role of leukotriene inhibitors in the treatment of childhood asthma.Arch Pediatr 2000; 7:969–975.PubMedCrossRefGoogle Scholar
  49. 49.
    Weisberg SC. Pharmacotherapy of asthma in children, with special reference to leukotriene receptor antagonists.Pediatr Pulmonol 2000; 29:46–61.PubMedCrossRefGoogle Scholar
  50. 50.
    Knorr B, Holland S, Rogers JD, Nguyen HH, Reiss TF. Montelukast adult (10-mg film-coated tablet) and pediatric (5-mg chewable tablet) dose selections.J Allergy Clin Immunol 2000, 106 (3 Suppl): S171–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Kemp JP, Dockhorn RJ, Shapiro Gget al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6 to 14-year old children with asthma.J Pediatr 1998, 133:424–428.PubMedCrossRefGoogle Scholar
  52. 52.
    Berkowitz NR, Schwartz E, Bukstein MDet al. Albuterol protects against exercise-induced asthma longer than metaproterenol sulfate.Pediatrics 1986; 77:173–178.PubMedGoogle Scholar
  53. 53.
    GreenCP, Price JF. Prevention of exercise-induced asthma by inhaled salmeterol xinafoate.Arch Dis Child 1992; 67:1014–1017.PubMedGoogle Scholar
  54. 54.
    Knorr B, Matz J, Bernstein Jet al. Montelukast for chronic asthma in 6-to 14-year-old children.JAMA 1998; 279:1181–1186.PubMedCrossRefGoogle Scholar
  55. 55.
    Bousquet J, Hejjaove A, Michel FB. Specific immunotherapy in asthma.J Allergy Clin Immunol 1990; 86:292–306.PubMedCrossRefGoogle Scholar
  56. 56.
    Pichler CE, Helbling A, Pichler WJ. Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergenspecific parameters and of nonspecific bronchial hyperreactivity.Allergy 2001; 56:301–306.PubMedCrossRefGoogle Scholar
  57. 57.
    Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunological effect of long term sublingual immunotherapy in asthmatic children sensitized to mites: a double blind, placebo-controlled study.Allergy 2000; 55:842–849.PubMedCrossRefGoogle Scholar
  58. 58.
    Ratageri VH, Kabra SK, Lodha Ret al. Lung function tests in asthma: which indices are better for assessment of severity?J Tropical Pediatr 2000; 47:57–59.CrossRefGoogle Scholar
  59. 59.
    Clark DJ, Lipworth BJ. Effect of multiple activations delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device.Thorax 1996; 51:981–984.PubMedGoogle Scholar
  60. 60.
    Wildahaber JH, Deradason SG, Haydon MJet al. Aerosol delivery to wheezy infants: A comparison between a nebulizer and two small volume spacer.Pediatr Pulmonol 1997; 23:121–26.Google Scholar
  61. 61.
    Chon KJ, Cunnigham SJ,Crain EF. Metered dose inhalers with spacers vs nebulisers for pediatric asthma.Arch Pediatr Adolesc Med 1995; 149:201–5.Google Scholar
  62. 62.
    Singhal T, Garg H, Arora HS, Lodha R, Pandey RM, Kabra SK. Efficacy of a home-made spacer with acute exacerbation of bronchial asthma: a randomized controlled trial.Indian J Pediatr 2001; 68:37–40.PubMedGoogle Scholar
  63. 63.
    Stahl E, Ribeiro LB, Sandhai G. Dose response to inhaled terbutaline powder and peak inspiratory flow through turbohaler in children with mild to moderate asthma. Pediatr Pulmonol 1996, 57:985–88.Google Scholar
  64. 64.
    Singh M, Kumar L. Randomized comparison of Dry Powder Inhaler and Metered Dose Inhaler with spacer. Management of children with asthma. Indian Pediar 2001, 38:24–28.Google Scholar
  65. 65.
    Watson WTA, Becker AB. Treatment of allergic rhinitis with intranasal corticosteroids in patients with mild asthma: Effect on lower airways responsiveness.J Allergy Clin Immunol 1993, 91:97–101.PubMedCrossRefGoogle Scholar
  66. 66.
    Oliveira CA, Sole D, Naspitz CKet al. Improvement of bronchial hyper responsiveness in asthmatic children treated for concomitant sinusitis.Am Allergy Asthma Immunol 1997; 79:70–74.CrossRefGoogle Scholar
  67. 67.
    Dykewicz MS. Newer and alternative non-steroidal treatments for asthmatic inflammation.Allergy Asthma Proc 2001; 22:11–15.PubMedCrossRefGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2003

Authors and Affiliations

  1. 1.Department of PediatricsAll India Institute of Medical SciencesNew DelhiIndia

Personalised recommendations